Letter to the editor regarding 'Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis'

dc.contributor.authorOnal, Cem
dc.contributor.authorOymak, Ezgi
dc.contributor.orcID0000-0002-2742-9021en_US
dc.contributor.pubmedID35239139en_US
dc.contributor.researcherIDD-5195-2014en_US
dc.date.accessioned2022-11-15T15:22:50Z
dc.date.available2022-11-15T15:22:50Z
dc.date.issued2022
dc.identifier.endpage1216en_US
dc.identifier.issn1699-048Xen_US
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85125556877en_US
dc.identifier.startpage1215en_US
dc.identifier.urihttp://hdl.handle.net/11727/8122
dc.identifier.volume24en_US
dc.identifier.wos000763958600002en_US
dc.language.isoengen_US
dc.relation.isversionof10.1007/s12094-022-02812-zen_US
dc.relation.journalCLINICAL & TRANSLATIONAL ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBODY RADIOTHERAPYen_US
dc.titleLetter to the editor regarding 'Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis'en_US
dc.typeLetteren_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: